Navidea to Host Moderated Q&A Webcast with Management

Marketing News – MarketingTools365 – Mktg News – Marketing Tools 365 – //// Business Marketing news and Mktg News : Navidea to Host Moderated Q&A Webcast with Management :

DUBLIN, Ohio–(BUSINESS WIRE)–$NAVB–Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The Company), a
company focused on the development of precision immunodiagnostic agents
and immunotherapeutics, announced today that it will hold an online
Question & Answer (Q&A) Session focused on Navidea’s clinical progress
in Nonalcoholic Steatohepatitis (NASH) with Jed Latkin, Chief Financial
and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of
Navidea, on Thursday June 21, 2018 at 5:00 p.m. Eastern Time. Investors
are invited to submit NASH-related questions they would like to hear
answered to ir@navidea.com or tpatel@edisongroup.com
by Wednesday, June 20, 2018.

 

Event:

Navidea IR Q&A Session – June 2018

Date:

Thursday, June 21, 2018

Time:

5:00 p.m. Eastern Time

Website:

www.navidea.com

 

For the June IR-focused Q&A Session, Navidea invites all interested
investors to submit questions they would like to see asked by Wednesday,
June 20, 2018 to ir@navidea.com or tpatel@edisongroup.com.

Details for the webcast link will be made available on the Investor
Relations section of Navidea’s website at www.navidea.com.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea’s Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company’s pipeline through global partnering and commercialization
efforts.

For more information, please visit http://www.navidea.com.

Contacts

Navidea Biopharmaceuticals
Jed Latkin, 614-551-3416
CFO/COO
jlatkin@navidea.com
or
Edison
Advisors
Tirth Patel, 646-653-7035
tpatel@edisongroup.com

. From Business Wire – Marketingtools365(COMM) – ATOM https://ift.tt/2JD6kgr Source : Navidea to Host Moderated Q&A Webcast with Management – https://ift.tt/2JD6kgr